SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AMLN (DIABETES DRUGS)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: D.Right who wrote (638)9/1/1997 4:53:00 PM
From: Henry Niman   of 2173
 
I expect Targretin approval (for CTCL) in 1998, BEFORE Pramlintide. I also expect Phase II diabetes data to be out by then (actually, I expect interim European data to come out this year, possibly this month) and I expect diabetics to demand Targretin to compliment Rezulin (once approved for CTCL, Targretin can be prescribed for any medically relevant indication). By the end of next year I think that far more diabetics will be taking Targretin than Pramlintide (I expect a MAJOR LGND diabetes deal this year, possibly this month). Targretin will be the NATURAL companion for Rezulin, which will have annual sales in the $100s of millions.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News